These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 19656320)

  • 1. Successful sulfonylurea treatment of an insulin-naïve neonate with diabetes mellitus due to a KCNJ11 mutation.
    Wambach JA; Marshall BA; Koster JC; White NH; Nichols CG
    Pediatr Diabetes; 2010 Jun; 11(4):286-8. PubMed ID: 19656320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved long-term glucose control in neonatal diabetes mellitus after early sulfonylurea allergy.
    Shah B; Breidbart E; Pawelczak M; Lam L; Kessler M; Franklin B
    J Pediatr Endocrinol Metab; 2012; 25(3-4):353-6. PubMed ID: 22768668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Permanent neonatal diabetes mellitus due to KCNJ11 mutation in a Portuguese family: transition from insulin to oral sulfonylureas.
    Dupont J; Pereira C; Medeira A; Duarte R; Ellard S; Sampaio L
    J Pediatr Endocrinol Metab; 2012; 25(3-4):367-70. PubMed ID: 22768671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transient neonatal diabetes with two novel mutations in the KCNJ11 gene and response to sulfonylurea treatment in a preterm infant.
    Siklar Z; Ellard S; Okulu E; Berberoğlu M; Young E; Savaş Erdeve S; Mungan IA; Hacihamdioğlu B; Erdeve O; Arsan S; Oçal G
    J Pediatr Endocrinol Metab; 2011; 24(11-12):1077-80. PubMed ID: 22308870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJ11 activating mutation from subcutaneous insulin to oral glyburide.
    Bremer AA; Ranadive S; Lustig RH
    Pediatr Diabetes; 2008 Jun; 9(3 Pt 1):236-9. PubMed ID: 18221420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
    Pearson ER; Flechtner I; Njølstad PR; Malecki MT; Flanagan SE; Larkin B; Ashcroft FM; Klimes I; Codner E; Iotova V; Slingerland AS; Shield J; Robert JJ; Holst JJ; Clark PM; Ellard S; Søvik O; Polak M; Hattersley AT;
    N Engl J Med; 2006 Aug; 355(5):467-77. PubMed ID: 16885550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case report: Better late than never, but sooner is better: switch from CSII to sulfonylureas in two patients with neonatal diabetes due to KCNJ11 variants.
    Mancioppi V; Pozzi E; Zanetta S; Missineo A; Savastio S; Barbetti F; Mellone S; Giordano M; Rabbone I
    Front Endocrinol (Lausanne); 2023; 14():1143736. PubMed ID: 37251668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea.
    Lau E; Correia C; Freitas P; Nogueira C; Costa M; Saavedra A; Costa C; Carvalho D; Fontoura M
    Arch Endocrinol Metab; 2015 Dec; 59(6):559-61. PubMed ID: 26331221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized medicine switching from insulin to sulfonylurea in permanent neonatal diabetes mellitus dictated by a novel activating ABCC8 mutation.
    Mak CM; Lee CY; Lam CW; Siu WK; Hung VC; Chan AY
    Diagn Mol Pathol; 2012 Mar; 21(1):56-9. PubMed ID: 22306677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early transition from insulin to sulfonylureas in neonatal diabetes and follow-up: Experience from China.
    Li X; Xu A; Sheng H; Ting TH; Mao X; Huang X; Jiang M; Cheng J; Liu L
    Pediatr Diabetes; 2018 Mar; 19(2):251-258. PubMed ID: 28791793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene.
    Slingerland AS; Nuboer R; Hadders-Algra M; Hattersley AT; Bruining GJ
    Diabetologia; 2006 Nov; 49(11):2559-63. PubMed ID: 17047922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a new KCNJ11 mutation.
    Ješić MM; Ješić MD; Maglajlić S; Sajić S; Necić S
    Diabetes Res Clin Pract; 2011 Jan; 91(1):e1-3. PubMed ID: 21056492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers.
    Stanik J; Gasperikova D; Paskova M; Barak L; Javorkova J; Jancova E; Ciljakova M; Hlava P; Michalek J; Flanagan SE; Pearson E; Hattersley AT; Ellard S; Klimes I
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1276-82. PubMed ID: 17213273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Genetics, Clinical Characteristics, and Treatment Outcomes of K
    Ngoc CTB; Dien TM; De Franco E; Ellard S; Houghton JAL; Lan NN; Thao BP; Khanh NN; Flanagan SE; Craig ME; Dung VC
    Front Endocrinol (Lausanne); 2021; 12():727083. PubMed ID: 34566892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An oral sulfonylurea in the treatment of transient neonatal diabetes mellitus.
    Loomba-Albrecht LA; Glaser NS; Styne DM; Bremer AA
    Clin Ther; 2009 Apr; 31(4):816-20. PubMed ID: 19446154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful transfer from insulin to oral sulfonylurea in a 3-year-old girl with a mutation in the KCNJ11 gene.
    Al-Mahdi M; Al Mutair A; Al Balwi M; Hussain K
    Ann Saudi Med; 2010; 30(2):162-4. PubMed ID: 20220270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2.
    Zung A; Glaser B; Nimri R; Zadik Z
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5504-7. PubMed ID: 15531505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful transition from insulin to sulfonylurea therapy in a patient with monogenic neonatal diabetes owing to a KCNJ11 F333L [corrected] mutation.
    Philla KQ; Bauer AJ; Vogt KS; Greeley SA
    Diabetes Care; 2013 Dec; 36(12):e201. PubMed ID: 24265373
    [No Abstract]   [Full Text] [Related]  

  • 19. Molecular and clinical features of K
    Hashimoto Y; Dateki S; Hirose M; Satomura K; Sawada H; Mizuno H; Sugihara S; Maruyama K; Urakami T; Sugawara H; Shirai K; Yorifuji T
    Pediatr Diabetes; 2017 Nov; 18(7):532-539. PubMed ID: 27681997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.
    Bowman P; Sulen Å; Barbetti F; Beltrand J; Svalastoga P; Codner E; Tessmann EH; Juliusson PB; Skrivarhaug T; Pearson ER; Flanagan SE; Babiker T; Thomas NJ; Shepherd MH; Ellard S; Klimes I; Szopa M; Polak M; Iafusco D; Hattersley AT; Njølstad PR;
    Lancet Diabetes Endocrinol; 2018 Aug; 6(8):637-646. PubMed ID: 29880308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.